164. Oculocutaneous albinism
15 clinical trials,   57 drugs   (DrugBank: 34 drugs),   34 drug target genes,   136 drug target pathways
Searched query = "Oculocutaneous albinism", "Hermansky-Pudlak syndrome", "Chediak-Higashi syndrome", "Griscelli syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01838655 (ClinicalTrials.gov) | April 16, 2013 | 20/4/2013 | Nitisinone for Type 1B Oculocutaneous Albinism | A Pilot Study of Nitisinone in the Treatment of Oculocutaneous Albinism, Type 1B | Albinism;Vision Loss | Drug: Nitisinone | National Eye Institute (NEI) | National Human Genome Research Institute (NHGRI) | Completed | 18 Years | N/A | All | 5 | Phase 1;Phase 2 | United States |